This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levine, R. A. Articles by Smith, C. Search for Related Content PubMed PubMed Citation Articles by Levine, R. A. Articles by Smith, C.

Tumor Suppressor PTEN is Mutated in Canine Osteosarcoma Cell Lines and Tumors

Departments of Molecular Medicine (RAL) and Biomedical Sciences (TF, CS), College of Veterinary Medicine, Cornell University, Ithaca, NY

Canine osteosarcoma (OS) cell lines contain mutations that directly or indirectly inactivate the tumor suppressor genes p53 and retinoblastoma. Another important tumor suppressor, PTEN, is mutated in many human cancers. To determine whether inactivation of PTEN plays a role in the pathogenesis of canine OS, we studied its expression in canine OS cell lines and tumors. Four of five canine OS cell lines (CO2, CO3, CO5, and CO7) constitutively express high levels of the phosphorylated form of Akt, an indirect indicator of aberrant PTEN expression. PTEN protein is essentially absent from three of these cell lines (CO2, CO5, and CO7), whereas CO3 contains a potentially inactivating amino acid substitution in PTEN at codon 340. Genomic hybridization experiments indicate that CO2, CO5, and CO7 contain large deletions within the PTEN gene. Ten of 15 OS tumors exhibit variable or negative PTEN staining. Evaluation of a PTEN-negative staining tumor by Southern blotting indicates that the PTEN gene is deleted in this tumor. These results indicate that PTEN is mutated or downregulated in a high percentage of canine OS cell lines and tumors and likely plays an important role in the pathogenesis of the disease.

Key words: Bone neoplasia; dogs; osteosarcoma; PTEN; tumorigenesis; tumor suppressor.

This article has been cited by other articles:

				N. K. Pryer, L. B. Lee, R. Zadovaskaya, X. Yu, J. Sukbuntherng, J. M. Cherrington, and C. A. London Proof of Target for SU11654: Inhibition of KIT Phosphorylation in Canine Mast Cell Tumors Clin. Cancer Res., November 15, 2003; 9(15): 5729 - 5734. [Abstract] [Full Text] [PDF]

				R. A. Levine Overexpression of the Sis Oncogene in a Canine Osteosarcoma Cell Line Vet. Pathol., May 1, 2002; 39(3): 411 - 412. [Abstract] [Full Text] [PDF]